Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No

Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S337-41. doi: 10.2337/dc09-S335.
No abstract available

Publication types

  • Comment
  • Review

MeSH terms

  • Administration, Oral
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control
  • Diabetic Angiopathies / epidemiology*
  • Diabetic Angiopathies / mortality
  • Diabetic Angiopathies / prevention & control
  • Disease Progression
  • Enzyme Inhibitors / therapeutic use
  • Gliclazide / therapeutic use
  • Glycoside Hydrolase Inhibitors
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Metformin / therapeutic use
  • Morbidity
  • Predictive Value of Tests
  • Sulfonylurea Compounds / therapeutic use
  • Thiazolidinediones / therapeutic use

Substances

  • Enzyme Inhibitors
  • Glycoside Hydrolase Inhibitors
  • Hypoglycemic Agents
  • Sulfonylurea Compounds
  • Thiazolidinediones
  • Metformin
  • Gliclazide